26

27

28

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF CALIFORNIA

| 2 | | FOR THE NORTHERN DISTRICT OF C. | ALIFORNIA | | |
|----------|----------------------|--|-------------------------|--|--|
| 3 | | HKLINE BEECHAM CORPORATION, doing | No. C 07-5702 CW | | |
| 4 | busi | ness as GLAXOSMITHKLINE, | VERDICT FORM | | |
| 5 | | Plaintiff, | | | |
| 6 | | V • | | | |
| 7 | ABBOTT LABORATORIES, | | | | |
| 8 | | Defendant. | | | |
| 9 | | / | | | |
| 10 | | T 119979000 071710 | | | |
| 11 | | I. ANTITRUST CLAIMS | | | |
| | | MONOPOLIZATION CLAIM | | | |
| 12 13 | A1. | Do you find that GSK has proven a valid market? | ly defined economic | | |
| 14 | | Yes ("Yes" is a finding for GSK.) | | | |
| 15 | | No ("No" is a finding for Abbott | .) | | |
| 16 17 | | If you answered "Yes" to this question, A2. If you answered "No" to this question Question B1. | | | |
| 18 | A2. | Do you find that GSK has proved that Abbin the relevant market? | oott had monopoly power | | |
| 19 | | Yes ("Yes" is a finding for GSK.) | | | |
| 20 | | No ("No" is a finding for Abbott | .) | | |
| 21 22 | | Whether you answered "Yes" or "No" to the Question A3. | nis question, answer | | |
| 23 | А3. | Do you find that GSK has proved that Abb following types of anticompetitive condu | | | |
| 24 | | a. a practical refusal to deal wa | ith its competitors? | | |
| 25 | | Yes ("Yes" is a finding for (| GSK.) | | |

("No" is a finding for Abbott.)

| 1 | | b. unlawful bundled discounting? |
|--|-----|---|
| 2 | | Yes ("Yes" is a finding for GSK.) |
| 3 | | No ("No" is a finding for Abbott.) |
| 4 | | If you answered "Yes" to Question A3a or A3b or both, proceed to Question A4. Otherwise, proceed to Question B1. |
| 5 6 | A4. | Do you find that Abbott has proved that it had a legitimate business reason for its conduct? |
| 7 | | Yes ("Yes" is a finding for Abbott.) |
| 8 | | No ("No" is a finding for GSK.) |
| 9 10 | | If you answered "Yes" to this question, proceed to Question B1. If you answered "No" to this question, proceed to Question A5. |
| 111213 | A5. | Do you find that GSK suffered injury to its business or property as a result of Abbott's monopolization of the relevant market, that this monopolization was a material cause of GSK's injury and that the injury was of the type that the antitrust laws were intended to prevent? |
| 14 | | Yes ("Yes" is a finding for GSK.) |
| 15 | | No ("No" is a finding for Abbott.) |
| 16 | | Proceed to Question A6. |
| 17 | | ATTEMPTED MONOPOLIZATION CLAIM |
| 18 | A6. | Did you find in Question Al above that GSK has proven a validly defined economic market? |
| 19 | | Yes ("Yes" is a finding for GSK.) |
| 20 21 | | No ("No" is a finding for Abbott.) |
| 22 | | If you answered "Yes" to this question, then answer Question A7. If you answered "No" to this question, proceed to Ouestion B1. |
| 2324 | A7. | Do you find that Abbott had a specific intent to acquire monopoly power in the relevant market? |
| 25 | | Yes ("Yes" is a finding for GSK.) |
| 26 | | No ("No" is a finding for Abbott.) |
| 27 | | If you answered "Yes" to this question, then answer Question |
| 28 | | 2 |

| 1 | | A8. If you answered "No" to this question, proceed to Question A12. |
|--------------------|------|---|
| 2 3 | A8. | Do you find that there was a dangerous probability that Abbott would acquire monopoly power in the relevant market? |
| 4 | | Yes ("Yes" is a finding for GSK.) |
| 5 | | No ("No" is a finding for Abbott.) |
| 6 7 | | If you answered "Yes" to this question, then answer Question A9. If you answered "No" to this question, proceed to Question A12. |
| 8 | A9. | Did you find in Question A3 above that GSK has proved that Abbott engaged in the following types of anticompetitive conduct: |
| 10 | | a. a practical refusal to deal with its competitors? |
| 11 | | Yes ("Yes" is a finding for GSK.) |
| 12 | | No ("No" is a finding for Abbott.) |
| 13 | | b. unlawful bundled discounting? |
| 14 | | Yes ("Yes" is a finding for GSK.) |
| 15 | | No ("No" is a finding for Abbott.) |
| 16 | | If you answered "Yes" to Question A9a or A9b or both, proceed to Question A10. Otherwise, proceed to Question B1. |
| 17 18 | A10. | Did you find in Question A4 above that Abbott has proved that it had a legitimate business reason for its conduct? |
| 19 | | Yes ("Yes" is a finding for Abbott.) |
| 20 | | No ("No" is a finding for GSK.) |
| 21 22 | | If you answered "Yes" to this question, then proceed to Question B1. If you answered "No" to this question, proceed to Question A11. |
| 23 24 25 | A11. | Do you find that GSK suffered injury to its business or property as a result of Abbott's attempted monopolization of the relevant market, that this attempted monopolization was a material cause of GSK's injury and that the injury was of the type that the antitrust laws were intended to prevent? |
| 26 | | Yes ("Yes" is a finding for GSK.) |
| 27 | | No ("No" is a finding for Abbott.) |
| <u>,</u> | | |

26

27

28

| 1 | | Proceed to Question A12. |
|---------------------------------|------|---|
| 2 3 | A12. | If you answered "Yes" to Question A5 or A11 or both, what amount of damages, if any, do you find GSK has proved it suffered in lost profits from the misconduct you found Abbott to have committed? |
| 4 | | \$ |
| 5 | | Proceed to Question B1. |
| 6 | | Troceca to gaestron br. |
| 7 8 | II. | BREACH OF THE IMPLIED COVENANT OF GOOD FAITH AND FAIR DEALING CLAIM |
| 9 | В1. | Do you find that Abbott breached the implied covenant of good faith and fair dealing that is implied in the Norvir Boosting License? |
| 10 | | Yes ("Yes" is a finding for GSK.) |
| 11 | | No ("No" is a finding for Abbott.) |
| 12 13 | | If you answered "Yes" to this question, then answer Question B2. If you answered "No" to this question, proceed to Question C1. |
| 1415 | в2. | Did Abbott engage in grossly negligent conduct when it breached the implied covenant of good faith and fair dealing? |
| 16 | | Yes ("Yes" is a finding for GSK.) |
| 17 | | No ("No" is a finding for Abbott.) |
| 18 | | If you answered "Yes" to this question, then answer Question B3. If you answered "No" to this question, proceed to |
| 19 | | Question C1. |
| 20 | Ⅱ | |
| 21 | | good faith and fair dealing was a proximate cause of the injury to GSK's business? |
| 22 | | Yes ("Yes" is a finding for GSK.) |
| 23 | | No ("No" is a finding for Abbott.) |
| 2425 | | If you answered "Yes" to this question, then answer Question B4. If you answered "No" to this question, proceed to Question C1. |

| | | c . | | | | |
|----------|---|--|--|--|--|--|
| 1 2 | | fair dealing? Enter the number below, even if you awarded some or all of these damages in Question A12 above. (The Court will ensure that GSK is not awarded the same damages more than once.) | | | | |
| 3 | | \$ | | | | |
| 4 | | Ť | | | | |
| 5 | | If you entered a number in this line, answer Question B5. Otherwise, proceed to Question C1. | | | | |
| 6 | в5. | How much of the damages you found in Question B4, if any, were | | | | |
| 7 | | NOT awarded in Question A12 above? | | | | |
| 8 | | \$ | | | | |
| 9 | Proceed to Question C1. | | | | | |
| 10 | | ADDITIONAL QUESTIONS | | | | |
| 11 | C1. | Did A | Abbott engage in any of the following? | | | |
| 12 | | a. | During the negotiation of the Norvir Boosting License, Abbott was considering how to use its control over Norvir | | | |
| 13 | | | to limit competition with Kaletra and deliberately withheld this from GSK. | | | |
| 14 | | | Yes ("Yes" is a finding for GSK.) | | | |
| 15 | | | No ("No" is a finding for Abbott.) | | | |
| 16 17 | | b. | Abbott inequitably asserted its power over Norvir by increasing Norvir's price by 400 percent to undermine and disrupt Lexiva's launch and future sales. | | | |
| 18 | | | Yes ("Yes" is a finding for GSK.) | | | |
| 19 | | | No ("No" is a finding for Abbott.) | | | |
| 20 | | С. | Abbott manipulated the timing of the 400-percent Norvir price increase in order to disrupt Lexiva's launch and | | | |
| 21 | | | undermine Lexiva's future sales. | | | |
| 22 | | | Yes ("Yes" is a finding for GSK.) | | | |
| 23 | | | No ("No" is a finding for Abbott.) | | | |
| 24 | | If yo | ou answered "Yes" to Question Cla, b, or c, or more than | | | |
| 25 | one of them, then answer Question C2. If you answered "No" to Questions C1a, b, and c, please have your presiding juror | | | | | |
| 26 | | STAII | , date and return your verdict. | | | |
| 27 | | | | | | |
| 28 | | | 5 | | | |

Case4:07-cv-05702-CW Document486 Filed03/24/11 Page6 of 6